Relay Therapeutics has launched with $57m in Series A venture capital to identify new drug targets and to find new ways of addressing difficult targets by studying proteins in motion rather than looking at static images.
“If a picture is worth a thousand words, a video is worth a thousand pictures,” Relay’s Executive Chairman and Interim...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)


